Background: Long-term exposure to high levels of arsenic is associated with increased risk for cardiovascular disease, whereas risk from long-term exposure to low to moderate arsenic levels (Ͻ100 g/L in drinking water) is unclear.
I
norganic arsenic in water and food (particularly rice and grain) is a major global health problem (1) . High arsenic levels in drinking water (Ͼ100 g/L) increased the risk for peripheral artery disease, coronary heart disease, stroke, and carotid atherosclerosis in studies conducted in Taiwan (2-4), Bangladesh (5, 6) , Chile (7), Inner Mongolia (8, 9) , and Pakistan (10, 11) . Less is known about the cardiovascular effects of low to moderate arsenic levels (Ͻ100 g/L in drinking water) in most populations because of a lack of prospective studies, limitations in exposure and outcome assessment, and inadequate information on cardiovascular risk factors (12, 13) . Indeed, the risk-benefit analysis that established the current U.S. standard for arsenic in drinking water (10 g/L) did not quantify the effect of arsenic on cardiovascular disease because of a lack of adequate data (14) .
In the United States, exposure to arsenic in drinking water disproportionately affects small rural communities in the Southwest, Midwest, and Northeast (15) . The Strong Heart Study is a population-based prospective cohort study of cardiovascular disease among 3 American Indian communities in rural Arizona, Oklahoma, and North and South Dakota ("the Dakotas") (16) . At the time of the study, arsenic levels in public drinking water systems were less than 10 g/L to 61 g/L in Arizona, less than 10 g/L in Oklahoma, and less than 1 g/L to 21 g/L in the Dakotas (17). In private wells, arsenic levels probably exceeded 10 g/L (and possibly 50 g/L in Arizona and the Dakotas) (15) . In Arizona and the Dakotas, drinking water was probably the main source of inorganic arsenic in study participants. Among participants in Oklahoma, as in other populations with low arsenic levels in drinking water (18, 19) , diet was probably the main source of arsenic exposure. Potential dietary sources of inorganic arsenic in the Strong Heart Study communities include rice, flour, and other grains (tacos, fry bread, and tortillas are especially common grain-based items). Thus, the objective of this study was to examine the prospective association of long-term arsenic exposure with cardiovascular disease over almost 20 years of follow-up in the Strong Heart Study.
METHODS

Study Population
The Strong Heart Study examined 4549 men and women aged 45 to 74 years at baseline between 1989 and 1991. Participants were invited to subsequent clinical visits between 1993 and 1995 and between 1998 and 1999 and were actively followed through 2008 (Appendix Figure 1 , available at www.annals.org). Every eligible person was invited to participate in Arizona and Oklahoma, whereas a cluster sampling technique was used in the Dakotas (20) . The participation rate was 62% (21) . Most participants were born in their communities and had lived there for their entire lives. Compared with nonparticipants, participants were similar in age, body mass index, and selfreported frequency of diabetes but were more likely to be female and to have self-reported hypertension (21) . The Indian Health Service, institutional review boards, and participating tribes approved the study protocol. All participants provided informed consent.
We used data from 3973 participants with sufficient urine available for arsenic measurements. We then excluded 273 participants with self-reported or clinical cardiovascular disease at baseline, 3 who were missing urinary creatinine data, and 122 who were missing other variables of interest, leaving 3575 participants for this analysis. Included participants were similar to those who were excluded because of missing data (not shown).
Data Collection
The clinical examinations consisted of a personal interview, physical examination, fasting blood test, and spot urine sample collection (20) . Trained and certified interviewers administered standardized questionnaires, and centrally trained nurses and medical assistants measured height, weight, and systolic and diastolic blood pressures and collected blood and urine according to standardized protocols (20) . Methods to measure blood pressure, cholesterol level, fasting glucose level, oral glucose tolerance, hemoglobin A 1c level, and plasma creatinine level have been described (20) . We defined hypertension as systolic blood pressure of 140 mm Hg or greater, diastolic blood pressure of 90 mm Hg or greater, or antihypertensive medication use. Low-density lipoprotein (LDL) cholesterol levels were calculated using the Friedewald equation for participants with triglyceride levels less than 4.5 mmol/L (Ͻ400 mg/dL), with missing values replaced by LDL levels measured using the ␤ quantification method. We defined albuminuria as a urinary albumin-creatinine ratio of 30 mg/g or greater (22). We used the Chronic Kidney Disease Epidemiology Collaboration formula (23) to calculate estimated glomerular filtration rate (eGFR) from recalibrated plasma creatinine measurements, age, and sex. Diabetes was defined as a fasting glucose level 7.0 mmol/L or greater (Ն126 mg/dL), 2-hour postload plasma glucose level 11.1 mmol/L or greater (Ն200 mg/dL), hemoglobin A 1c level 6.5% or greater, or self-reported use of insulin or an oral hypoglycemic agent.
Spot urine samples collected the morning of the baseline clinical examination were frozen within 1 to 2 hours of collection and stored at Ϫ70°C or lower (20) . Urinary albumin and creatinine levels were measured by an automated nephelometric immunochemical procedure and an automated alkaline picrate method, respectively (20) .
Urinary Arsenic
To assess long-term arsenic exposure, we measured arsenic species concentrations in urine. The analytic methods and associated quality control criteria for arsenic analysis have been described in detail (24) . Arsenic species concentrations were determined by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry that served as the arsenic selective detector (Agilent 1100 HPLC and Agilent 7700x ICP-MS, Agilent Technologies, Santa Clara, California). Arsenic speciation distinguishes species directly related to inorganic arsenic exposure (arsenite, arsenate, monomethylarsonate [MMA] , and dimethylarsinate [DMA]) from those related to organic arsenicals in seafood (arsenobetaine as an overall marker of seafood arsenicals), which are generally considered nontoxic (1). The limit of detection for inorganic arsenic (arsenite plus arsenate), MMA, DMA, and arsenobetaine plus other cationic arsenic species was 0.1 g/L (24). For participants with arsenic species concentrations below the limit of detection (5.1% for inorganic arsenic, 0.8% for MMA, 0.03% for DMA, and 2.1% for arsenobetaine), levels were imputed as the limit of detection divided by the square root of 2. The interassay coefficients of
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Long-term exposure to high levels of inorganic arsenic in water and food, particularly rice and grains, is associated with increased risk for cardiovascular disease.
Contribution
This prospective cohort study involving 3575 rural American Indian men and women found that long-term exposure to low to moderate levels of arsenic, as measured in urine, was associated with increased risk for fatal and nonfatal cardiovascular disease.
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Original Research Arsenic Exposure and Incident Cardiovascular Disease variation for inorganic arsenic, MMA, DMA, and arsenobetaine for an in-house reference urine sample were 6.0%, 6.5%, 5.9%, and 6.5%, respectively (24) .
We used the sum of urinary inorganic arsenic (arsenite and arsenate) and methylated arsenic species (DMA and MMA) as a biomarker to integrate inorganic arsenic exposure from multiple sources (1, 25, 26) . To account for urine dilution, urinary arsenic concentrations were divided by urinary creatinine levels and expressed as "g/g creatinine." Low urinary concentrations of arsenobetaine (median, 0.76 g/g creatinine; interquartile range, 0.48 to 1.70 g/g creatinine) confirmed that seafood intake was low in this sample, indicating that measured methylated species reflect inorganic arsenic exposure. Inorganic arsenic, MMA, and DMA have estimated half-lives of 38, 9, and 2 days, respectively (27, 28) . In a random sample stratified by study region of 380 participants with 3 repeated arsenic measures over 10 years, the intraclass correlation coefficient for the log-transformed sum of inorganic and methylated arsenic species was 0.64 (95% CI, 0.60 to 0.69) and the average change in urinary arsenic concentrations between the first and third visits was Ϫ0.8 g/g creatinine.
Cardiovascular Disease Incidence and Mortality Follow-up
Incident cardiovascular end points during follow-up were identified by annual contact, by review of hospitalization and death records, and during 2 clinic visits conducted between 1993 and 1995 and between 1998 and 1999. Follow-up through 2008 was 99.8% complete for mortality and 99.2% complete for nonfatal events. When possible cardiovascular events were identified, medical records were abstracted and mortality and morbidity review committees adjudicated cardiovascular events (20) . Detailed definitions of the criteria used by the review committees have been described previously (20, 29) and are included in the Supplement (available at www.annals.org).
We defined incident coronary heart disease as the first occurrence of definite nonfatal coronary heart disease or definite and possible fatal coronary heart disease. Incident stroke was defined as the first occurrence of a definite nonfatal stroke or a definite or possible fatal stroke. We defined incident cardiovascular disease as the first occurrence of coronary heart disease or stroke, as previously defined; definite nonfatal congestive heart failure; or other fatal cardiovascular disease.
Follow-up extended from the date of the baseline examination until the date of the cardiovascular event, the date of death, or 31 December 2008, whichever occurred first. The mean follow-up time among participants without a cardiovascular event was 15.0 years.
Statistical Analysis
We evaluated the prospective association of urinary arsenic concentrations with incident cardiovascular disease by using Cox proportional hazards models with age as time scale and individual entry times (age at baseline) treated as staggered entries. Urinary arsenic concentrations were modeled as quartiles, log-transformed concentrations to compare the 75th and 25th percentiles (interquartile range), and log-transformed concentrations with restricted quadratic splines. We allowed the nonparametric underlying baseline hazards to differ by region because study locations differed by urinary arsenic concentrations (17) and cardiovascular risk factors (16) . Models were progressively adjusted (see footnotes of Tables 1 and 2) . P values for linear and nonlinear trends were obtained from Wald tests for log-transformed arsenic coefficients and restricted quadratic spline coefficients, respectively. We found no violations of the proportional hazards assumption over time based on visual examinations of smoothed association between age and scaled Schoenfeld residuals over time and a test for a nonzero slope for this association (30) . To estimate absolute rates, we used Poisson regression to model cardiovascular disease incidence and mortality and then estimated the marginal response for each arsenic quartile given mean values of covariates. Poisson models were adjusted for model 2 covariates, age, and study region.
We conducted several sensitivity analyses. First, we evaluated the association of cardiovascular disease end points with arsenobetaine, a nontoxic seafood arsenical (1). We hypothesized that arsenobetaine would not be associated with cardiovascular disease. Second, we evaluated alternative methods to adjust spot urine samples for urine dilution. We measured urinary arsenic concentrations in g/L and adjusted the models for log-transformed urinary creatinine concentrations. For participants without diabetes or albuminuria (n ϭ 1646), we also used urinary arsenic concentrations adjusted to the mean specific gravity of 1.017 (31) . The specific gravity of urine is less dependent on muscle mass and nutritional status than urinary creatinine (31) , but this adjustment is inadequate if albumin or glucose is present in urine (32). Both analyses resulted in similar findings (not shown).
We performed subgroup analyses to evaluate effect modification in adjusted models by including quantitative interaction terms for log-transformed urinary arsenic concentrations with indicator variables for age groups; sex; smoking status; diabetes status; study region; and proportions of inorganic arsenic, MMA, and DMA in separate models. On the basis of prior evidence (6), we hypothesized that the association between arsenic exposure and incident cardiovascular disease would be stronger in current smokers and in participants with higher proportions of MMA and lower proportions of DMA in urine. Other subgroup analyses were exploratory without a priori hypotheses. P values for interactions were obtained using Wald tests for multiple coefficients.
Arsenic methylation patterns have been related to differences in cardiovascular end points in populations from Taiwan (4, 33). To evaluate the potential role of arsenic metabolism, we examined the relationship between the 
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RESULTS
Over 45 738 person-years of follow-up, 439 participants died of cardiovascular disease (341 coronary heart disease deaths and 54 stroke deaths) and 1184 participants developed fatal or nonfatal cardiovascular disease (846 incident coronary heart disease events and 264 incident strokes). Overall, the median urinary arsenic concentration was 9.7 g/g creatinine (interquartile range, 5.8 to 15.7 g/g creatinine; range, 0.1 to 183.4 g/g creatinine). Urinary arsenic concentrations varied by study region; the medians were 14.2, 5.6, and 10.6 g/g creatinine in Arizona, Oklahoma, and the Dakotas, respectively. Increasing baseline arsenic concentrations were associated with female sex, lower educational attainment, lower LDL cholesterol level, higher eGFR, increased prevalence of never-smokers, and increased prevalence of diabetes ( Table 3) .
Baseline urinary arsenic concentrations were prospectively associated with cardiovascular disease mortality and incidence (Tables 1 and 2 [model 2]). The fully adjusted hazard ratios for cardiovascular disease, coronary heart disease, and stroke mortality when the highest and lowest quartiles of urinary arsenic concentrations were compared were 1.65 (CI, 1.20 to 2.27; P for trend Ͻ 0.001), 1.71 (CI, 1.19 to 2.44; P for trend Ͻ 0.001), and 3.03 (CI, 1.08 to 8.50; P for trend ϭ 0.061), respectively ( § Obtained from Cox proportional hazards models with log-transformed arsenic as a continuous variable. Adjustment for systolic blood pressure and hypertension medication use instead of hypertension and for hemoglobin A 1c levels instead of diabetes produced similar results (data not shown). ¶ Stratified by study center and adjusted for age (age as time metric and age at baseline were treated as staggered entries). ** Further adjusted for sex, education (none, some, or high school), smoking status (never, former, or current), body mass index (kg/m 2 ), and low-density lipoprotein cholesterol level (mg/dL).
† † Further adjusted for hypertension (yes or no), diabetes (yes or no), and estimated glomerular filtration rate (mL/min/1.73 m 2 ). ‡ ‡ Further adjusted for albuminuria (yes or no). for cardiovascular disease incidence. The dose-response relationships of arsenic concentrations with cardiovascular disease and coronary heart disease incidence and mortality were statistically significant (Tables 1 and 2), with no significant departures from linearity (Figure 1 ). For stroke incidence and mortality, the dose-response relationship was positive but not statistically significant ( Tables 1 and 2 and Appendix Figure 2 , available at www.annals.org).
For cardiovascular and coronary heart disease mortality, the associations were positive for all subgroups but stronger among participants from Arizona, those with diabetes, and those with proportions of DMA above the median (Appendix Figure 3 , available at www.annals.org). For cardiovascular and coronary heart disease incidence, the associations with urinary arsenic were stronger among women, never-smokers, participants from Arizona, participants with diabetes, and participants with proportions of DMA above the median (Appendix Figures 4 and 5 , available at www.annals.org). For stroke incidence, the associations were consistent across the subgroups evaluated (Appendix Figure 6 , available at www.annals.org). In dose-response analyses, the associations of arsenic with cardiovascular disease mortality and incidence were stronger in participants from Arizona (Figure 2 ) and those with diabetes ( Figure 3) .
Urinary arsenobetaine was not associated with any of the cardiovascular end points (data not shown). The fully adjusted hazard ratios for cardiovascular disease mortality and incidence were 0.93 (CI, 0.83 to 1.04) and 0.95 (CI, § Obtained from Cox proportional hazards models with log-transformed arsenic as a continuous variable. Adjustment for systolic blood pressure and hypertension medication use instead of hypertension and for hemoglobin A 1c levels instead of diabetes produced similar results (data not shown). ¶ Stratified by study center and adjusted for age (age as time metric and age at baseline were treated as staggered entries). ** Further adjusted for sex, education (none, some, or high school), smoking status (never, former, or current), body mass index (kg/m 2 ), and low-density lipoprotein cholesterol level (mg/dL).
† † Further adjusted for hypertension (yes or no), diabetes (yes or no), and estimated glomerular filtration rate (mL/min/1.73 m 2 ). ‡ ‡ Further adjusted for albuminuria (yes or no). 0.88 to 1.01), respectively, when the 25th and 75th percentiles of arsenobetaine concentrations were compared. In the subset of participants with detectable inorganic arsenic, MMA, and DMA (n ϭ 3381), hazard ratios for incident cardiovascular disease when an interquartile range of the proportions of inorganic arsenic, MMA, and DMA was compared were 0.91 (CI, 0.84 to 0.99), 0.98 (CI, 0.90 to 1.07), and 1.04 (CI, 0.96 to 1.12), respectively, after adjustment for sex, education, smoking, body mass index, LDL cholesterol level, and the sum of inorganic and methylated arsenic species (g/g creatinine). We found no associations between any of the biomarkers of arsenic metabolism and other study end points (not shown).
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DISCUSSION
Exposure to low to moderate levels of inorganic arsenic, as measured in urine, was prospectively associated with fatal and nonfatal cardiovascular disease in a sample of rural American Indians with a high burden of diabetes and cardiovascular disease. The associations persisted after adjustment for sociodemographic factors, smoking, and lipid levels and were attenuated with further adjustment for hypertension, diabetes, and measures of kidney disease, variables that could be in the causal pathway. The associations were largely similar for coronary heart disease and stroke and were stronger for cardiovascular mortality than for cardiovascular incidence. Urinary arsenobetaine, an organic arsenical that is found in seafood and is believed to be nontoxic, was not associated with cardiovascular disease. Overall, our findings support an association between longterm exposure to low to moderate levels of inorganic arsenic and incident cardiovascular disease.
The adverse cardiovascular effects of long-term exposure to high arsenic levels in drinking water (Ͼ100 g/L) have long been recognized (34) . In early case reports, exposure to high arsenic levels was associated with peripheral artery disease in southwestern Taiwan and in German vintners (35) and with myocardial infarction in young adults from Chile (36) . Long-term exposure to high levels of arsenic in drinking water was prospectively associated with coronary heart disease mortality in southwestern Taiwan (3). Recently, prospective studies from Bangladesh found that urine and drinking water arsenic concentrations were associated with increased cardiovascular disease and coronary heart disease mortality (5, 6). Evidence from multiple countries with different ethnic backgrounds supports a causal association between long-term exposure to high levels of arsenic and cardiovascular disease (12, 13) .
Less is known about the cardiovascular effects of arsenic at levels less than 100 g/L in drinking water. Some (37-44), but not all (45, 46) , studies have found modestly increased cardiovascular risks, although most of these studies had important limitations, including ecological designs, limited exposure and outcome assessment, and lack of adjustment for cardiovascular risk factors. In 2 recent prospective studies from Bangladesh, the hazard ratios for low to moderate arsenic exposure categories (arsenic concentrations in drinking water of 12.1 to 62 g/L vs. Յ12 g/L [6] and 10 to 49 g/L vs. Ͻ10 g/L [5] ) and cardiovas- Experimental studies also support the role of arsenic in cardiovascular disease. Animals exposed to arsenic were more likely to develop atherosclerotic plaque than unexposed animals (47) (48) (49) . Potential mechanisms for arsenicrelated atherosclerosis include endothelial dysfunction, smooth-muscle proliferation, angiogenesis and apoptosis, vascular injury, and platelet aggregation (50, 51) . In addition, arsenic upregulates inflammation, disrupts lipid metabolism, and increases lipid oxidation (50, 51) . Arsenicrelated cardiovascular disease could also be mediated by other cardiovascular risk factors, including hypertension (52), diabetes (53, 54) , and kidney disease (55) (56) (57) .
Our subgroup analyses must be interpreted cautiously. Some studies have reported differences by smoking status (6), urinary arsenic metabolic patterns (4, 33) , and genetic factors (58). In our study, we found stronger associations among never-smokers, contrary to a stronger association among current smokers in a prospective cohort study in Bangladesh (6) . Susceptibility to arsenic toxicity may also differ by sex (59) , although previous studies of arsenic and cardiovascular disease found no marked differences by sex (2, 10, 35, 40, 45) . We found a stronger association among women, although arsenic was associated with an increased risk for cardiovascular disease in both sexes. In studies eval- Solid lines represent adjusted hazard ratios based on restricted quadratic splines for the log-transformed sum of inorganic and methylated arsenic species, with knots at the 10th, 50th, and 90th percentiles (3.8, 9.7, and 24.0 g/g creatinine, respectively). The dotted lines represent upper and lower 95% CIs. The reference was set at the 10th percentile of the arsenic distribution (3.8 g/g creatinine). Adjustment factors were the same as those for model 2 in Tables 1 and 2 . The bars represent a histogram of urinary arsenic distribution among participants (the extreme tails of the histogram were truncated because only 1 participant had a urinary arsenic level Ͻ1.6 g/g creatinine and 31 had a level Ͼ54.6 g/g creatinine).
Original Research uating the health effects of arsenic metabolism conducted in Taiwan, individuals with a higher proportion of MMA or lower proportion of DMA in urine had a higher risk for peripheral artery disease (4), carotid atherosclerosis (33), and hypertension (60) . In addition, the association between arsenic exposure and cardiovascular disease was stronger among participants with a higher proportion of MMA (4, 33). In our study, which examined exposure to low to moderate arsenic levels, we found no association between arsenic metabolic patterns in urine and cardiovascular risk. The association between arsenic and cardiovascular disease, on the other hand, was stronger among participants with a higher proportion of DMA. Additional research is needed to evaluate the effect modification of Figure 2 . Hazard ratios for cardiovascular disease incidence and mortality, stratified by study region.
The lines represent adjusted hazard ratios based on restricted quadratic splines for the log-transformed sum of inorganic and methylated arsenic species, with knots at the 10th, 50th, and 90th percentiles (3.8, 9.7, and 24.0 g/g creatinine, respectively). The reference was set at the 10th percentile of the arsenic distribution (3.8 g/g creatinine). Adjustment factors were the same as those for model 2 in Tables 1 and 2 . The bars represent a histogram of urinary arsenic distribution among participants (the extreme tails of the histogram were truncated because only 1 participant had a urinary arsenic level Ͻ1.6 g/g creatinine and 31 had urinary arsenic levels Ͼ54.6 g/g creatinine). The lines represent adjusted hazard ratios based on restricted quadratic splines for the log-transformed sum of inorganic and methylated arsenic species, with knots at the 10th, 50th, and 90th percentiles (3.8, 9.7, and 24.0 g/g creatinine, respectively). The reference was set at the 10th percentile of the arsenic distribution (3.8 g/g creatinine). Adjustment factors were the same as those for model 2 in Tables 1 and 2 . The bars represent a histogram of urinary arsenic distribution among participants (the extreme tails of the histogram were truncated because only 1 participant had a urinary arsenic level Ͻ1.6 g/g creatinine and 31 had urinary arsenic levels Ͼ54.6 g/g creatinine).
Original Research Arsenic Exposure and Incident Cardiovascular Disease arsenic exposure by arsenic metabolism in populations exposed to low to moderate arsenic levels. We also found differences in the association between arsenic and cardiovascular disease end points by study region and diabetes status, subgroups that have not been evaluated before. The stronger association in Arizona than in other regions could be related to higher arsenic exposure, residual confounding, effect modification by other co-exposures, differences in access to care and surveillance methods across the 3 study regions, or gene-arsenic interactions. In a previous linkage study in the Strong Heart Family Study, we found different peaks across the genome associated with arsenic metabolism measures across study regions (61) . We found stronger associations among participants with diabetes than among those without it. Arsenic has been consistently associated with diabetes in populations exposed to high levels in drinking water (54) , and recent prospective studies from the United States that examined exposure to low to moderate levels, including among American Indians in the Southwest, support arsenic exposure as a diabetes risk factor (62, 63) . Diabetes could be in the causal pathway between arsenic exposure and cardiovascular disease. Alternatively, it could confound the association between arsenic exposure (as measured in urine) and cardiovascular disease. In the Strong Heart Study, baseline urinary arsenic levels were associated with poor diabetes control (53) . However, further adjustment for hemoglobin A 1c levels in this analysis produced similar results. Overall, the stronger association between arsenic and cardiovascular disease among participants with diabetes must be interpreted cautiously and requires replication in other populations. Hypertension (64) and kidney disease (55-57) could also be in the causal pathway. Including these variables in the models could have resulted in overadjustment.
Strengths of this study include high-quality data collection methods and surveillance for cardiovascular disease outcomes over a long follow-up (20) and rigorous laboratory methods for measuring concentrations of urinary arsenic species (24) . Urinary arsenic measurements integrate all sources of exposure at the individual level, including water and food, and are an excellent biomarker of internal dose (1, 25, 26) . This study also had several limitations. We measured urinary arsenic levels in a single sample at baseline, and individual levels in drinking water were unavailable. The temporal stability of arsenic levels in public and private drinking water and in urine has been shown in several studies in the United States (17, [65] [66] [67] . Several studies have also shown consistent associations with cardiovascular end points when arsenic levels measured in water and urine were compared (4, 6) . Other limitations include the possibility of residual confounding (for example, access to care or geographic factors), overadjustment for variables that could be in the causal pathway (diabetes, hypertension, or kidney disease), and exposure and outcome misclassification.
More than 100 million persons worldwide are exposed to arsenic levels in drinking water above the World Health Organization standard of 10 g/L (68, 69). In 2001, the U.S. Environmental Protection Agency estimated that 13 million Americans were exposed to levels above 10 g/L (14). Many more millions are exposed to arsenic through food, although no standards for inorganic arsenic in food currently exist. Given the large population exposed, even a modest increased risk for cardiovascular disease due to arsenic could have important public health implications. Cardiovascular disease is the leading cause of death in the United States, with rates among American Indians exceeding those of the general U.S. population (70). Arsenic mitigation could reduce the burden of cardiovascular disease. Discussions to revise the current U.S. Environmental Protection Agency safety standard for arsenic in drinking water should quantitatively consider the evidence supporting the cardiovascular disease effects of exposure to low to moderate levels of arsenic.
In conclusion, exposure to low to moderate levels of inorganic arsenic, as measured in urine, was prospectively associated with increased fatal and nonfatal cardiovascular disease in a U.S. population with a high burden of diabetes and cardiovascular disease. These findings support the importance of exposure to low to moderate arsenic levels as a cardiovascular risk factor with no apparent threshold. Note: Ms. Moon and Dr. Navas-Acien had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
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